RXST Stockholders with Large Losses Should Contact Robbins LLP for Information About the RxSight, Inc. Class Action

Core Viewpoint - A class action has been filed against RxSight, Inc. for allegedly misleading investors about product demand and financial performance during a specified period [1][2]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) for cataract surgery in the U.S. [1] - The primary product of the company is the RxSight system, which includes the LAL and the Light Delivery Device (LDD) [1]. Allegations - The complaint alleges that during the class period, RxSight failed to disclose significant issues, including: - Adoption challenges and structural issues leading to declines in sales and utilization [2] - Overstated demand for its products [2] - Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [3]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [3]. - Following this news, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025 [3].